Relief of upper urinary tract obstruction in patients with cancer of the prostate;Aflastning af tumorbetinget obstruerede øvre urinveje ved prostatacancer

Ugeskrift for Laeger

Volumn 171, Issue 11, 2009, Pages 873-876

  Kræmer, Pia Charlotte ^a   Borre, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; HUMAN; HYDRONEPHROSIS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PERCUTANEOUS NEPHROSTOMY; PROSTATE TUMOR; RETROSPECTIVE STUDY; STENT; URETER OBSTRUCTION; URINARY DIVERSION;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; HYDRONEPHROSIS; MALE; MIDDLE AGED; NEPHROSTOMY, PERCUTANEOUS; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STENTS; URETERAL OBSTRUCTION; URINARY CATHETERIZATION; URINARY DIVERSION;

EID: 62849089344     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. The Danish Health Organisation. www.sst.dk/publ/tidsskrifter/nyetal/pdf/2006/02_06.pdf (august 2008).
2. www.cancer.dk.
3. Breslow N, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
4. Prostatacancerbetænkning 2005. Klaringsrapport fra Dansk Urologisk Selskab. www.urologi.dk/menu/DUS.htm (januar 2008).
5. Jønler M, Pedersen KV. Diagnose, udredning og opfølgning af patienter med prostatacancer. Ugeskr læger 2007;20:1889-91.
6. Ku JH., Lee SW, Jeon HG et al. Percutaneous nephrostomy versus inwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences? Urology 2004;64:895-9.
7. Chung SY, Stein RJ, Landsittel D et al. 15-year experience with the mangement of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004;172:592-5.
8. Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 2005;96:41-6.
9. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.